New combination treatment for relapsed mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination treatment for mantle cell lymphoma that has returned or not responded to standard therapies. The goal is to see if the combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have mantle cell lymphoma that came back or didn't respond to earlier treatment, and you've had both antibody therapy and a BTK inhibitor, or you couldn't take a BTK inhibitor.
- You have at least one tumor that can be measured on scans.
- You are generally able to care for yourself (up and about, no bed rest needed) — this is called an ECOG score of 0–2.
- You can provide a tumor tissue sample (from a past biopsy or a new one) and are willing to follow the study schedule and use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
This Phase 2 trial studies whether an “extra chemo” schedule (adding cytarabine) can work better than a standard rituximab-bendamustine plan in older people with mantle cell lymphoma. It compares two treatment sequences to see which one helps patients live longer and respond better with acceptable safety.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.